Back to today’s briefing

Story perspectives

New Study: Cold Virus Infections Don’t Affect COVID Vaccines

7/18/2025

46 8

Summary

Sanofi Advances Vaccines

A groundbreaking study by Sanofi Vaccines R&D reveals that previous infections with common cold coronaviruses have no impact on the immune response to SARS-CoV-2 vaccines. In a parallel effort, researchers at the Centenary Institute have created CoVEXS5, a promising vaccine candidate that effectively shields against various coronavirus variants, demonstrating remarkable efficacy in mice and the potential for worldwide distribution.

Summary

Researchers Unveil Vaccine

Researchers from Northwestern and Cornell universities have unveiled a groundbreaking, rapid method for producing nanoparticle vaccines against the deadly Nipah virus, which carries a staggering 75% fatality rate. This innovative approach promises swift vaccine creation, paving the way for improved global access and readiness for future pandemics, underscoring the urgent need for efficient vaccine development.

1 of 2

Sanofi Advances Vaccines

A groundbreaking study by Sanofi Vaccines R&D reveals that previous infections with common cold coronaviruses have no impact on the immune response to SARS-CoV-2 vaccines. In a parallel effort, researchers at the Centenary Institute have created CoVEXS5, a promising vaccine candidate that effectively shields against various coronavirus variants, demonstrating remarkable efficacy in mice and the potential for worldwide distribution.

1 / 2